The treatment and prevention of deep vein thrombosis in the preoperative management of patients who have neurologic diseases

Neurologic Clinics

Volumn 22, Issue 2, 2004, Pages 423-439

  Farray, Daniel ^a   Carman, Teresa L ^b   Fernandez Jr , Bernardo B ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b JOBST VASCULAR CENTER   (United States)

^c DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; XIMELAGATRAN;

BLEEDING; COMPRESSION THERAPY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MOBILIZATION; NEUROLOGIC DISEASE; NEUROSURGERY; PREOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK; RISK FACTOR; SURGICAL PATIENT; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT CONTRAINDICATION; VENOUS THROMBOEMBOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; BRAIN DISEASES; CHONDROITIN SULFATES; DERMATAN SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARITIN SULFATE; HUMANS; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOSIS; WARFARIN;

EID: 1642359859     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2004.01.002     Document Type: Review

References (78)

1. Geerts W.H., Heit J.A., Clagett G.P., Pineo G.F., Colwell C.W., Anderson F.A. Jr., et al. Prevention of venous thromboembolism. Chest. 119:(Suppl 1):2001;132S-175S.
2. Colditz G.A., Tuden R.L., Oster G. Rates of venous thrombosis after general surgery: combined results of randomised clinical trials. Lancet. 2:1986;143-146.
3. Hamilton M.G., Hull R.D., Pineo G.F. Venous thromboembolism in neurosurgery and neurology patients: a review. Neurosurgery. 34:1994;280-296.
4. Hirsh J., Warkentin T.E., Shaughnessy S.G., Anand S.S., Halperin J.L., Raschke R., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 119:(Suppl 1):2001;64S-94S.
5. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 332:1995;1330-1335.
6. Deitcher S.R., Carman T.L. Heparin-induced thrombocytopenia: natural history, diagnosis, and management. Vasc Med. 6:2001;113-119.
7. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet. 2:1975;45-51.
8. Collins R., Scrimgeour A., Yusuf S., Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 318:1988;1162-1173.
9. Clagett G.P., Reisch J.S. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 208:1988;227-240.
10. Leyvraz P.F., Bachmann F., Hoek J., Buller H.R., Postel M., Samama M., et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ. 303:1991;543-548. [erratum: BMJ 1991;303:1243].
11. Mismetti P., Laporte S., Darmon J.Y., Buchmuller A., Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 88:2001;913-930.
12. Koch A., Bouges S., Ziegler S., Dinkel H., Daures J.P., Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg. 84:1997;750-759.
13. Palmer A.J., Schramm W., Kirchhof B., Bergermann R. Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomized clinical trials. Haemostasis. 27:1997;65-74.
14. Nurmohamed M.T., Rosendaal F.R., Buller H.R., Dekker E., Hommes D.W., Vandenbroucke J.P., et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 340:1992;152-156.
15. Francis C.W., Pellegrini V.D. Jr., Leibert K.M., Totterman S., Azodo M.V., Harris C.M., et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thromb Haemost. 75:1996;706-711.
16. Prandoni P., Bruchi O., Sabbion P., Tanduo C., Scudeller A., Sardella C., et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med. 162:2002;1966-1971.
17. Hull R., Raskob G., Pineo G., Rosenbloom D., Evans W., Mallory T., et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 329:1993;1370-1376.
18. Gross M., Anderson D.R., Nagpal S., O'Brien B. Venous thromboembolism prophylaxis after total hip or knee arthroplasty: a survey of Canadian orthopedic surgeons. Can J Surg. 42:1999;457-461.
19. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106. [erratum: BMJ 1994;308:1540].
20. Pulmonary Embolism Prevention Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin. Pulmonary Embolism Prevention (PEP) trial. Lancet. 355:2000;1295-1302.
21. Cohen A., Quinlan D. PEP trial. Pulmonary embolism prevention. Lancet. 356:2000;247.
22. Elalamy I., Hatmi M. What is the place of aspirin in venous thrombosis prophylaxis? Ann Cardiol Angeiol (Paris). 51:2002;296-302.
23. Wille-Jorgensen P. New therapeutic options in DVT prophylaxis. Orthopedics. 23:(Suppl 6):2000;s639-s642.
24. Comp P.C., Voegeli T., McCutchen J.W., Skoutakis V.A., Trowbridge A., Overdyke W.L. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: the Danaparoid Hip Arthroplasty Investigators Group. Orthopedics. 21:1998;1123-1128.
25. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. The TIFDED Study Group. Haemostasis. 29:1999;310-317.
26. Wade W.E. Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery. Am J Orthop. 28:1999;229-231.
27. Eriksson B.I., Ekman S., Kalebo P., Zachrisson B., Bach D., Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 347:1996;635-639.
28. Eriksson B.I., Ekman S., Lindbratt S., Baur M., Bach D., Torholm C., et al. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am. 79:1997;326-333.
29. Eriksson B.I., Wille-Jorgensen P., Kalebo P., Mouret P., Rosencher N., Bosch P., et al. A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 337:1997;1329-1335.
30. Turpie A.G., Bauer K.A., Erikson B.I., Lassen M.R. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 162:2002;1833-1840.
31. Turpie A.G., Eriksson B.I., Lassen M.R., Bauer K.A. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc. 11:2002;182-188.
32. Francis C.W., Davidson B.L., Berkowitz S.D., Lotke P., Ginsberg J.S., Lieberman J.R., et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med. 137:2002;648-655.
33. Heit J.A., Colwell C.W., Francis C.W., Ginsberg J.S., Berkowitz S.D., Whipple J., et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med. 161:2001;2215-2221.
34. Flam E., Berry S., Coyle A., Dardik H., Raab L. Blood-flow augmentation of intermittent pneumatic compression systems used for prevention of deep vein thrombosis prior to surgery. Am J Surg. 171:1996;312-315.
35. Tarnay T.J., Rohr P.R., Davidson A.G., Stevenson M.M., Byars E.F., Hopkins G.R. Pneumatic calf compression, fibrinolysis, and the prevention of deep venous thrombosis. Surgery. 88:1980;489-496.
36. Comerota A.J., Chouhan V., Harada R.N., Sun L., Hosking J., Veermansunemi R., et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg. 226:1997;306-313.
37. Turpie A.G., Delmore T., Hirsh J., Hull R., Genton E., Hiscoe C., et al. Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. Thromb Res. 15:1979;611-616.
38. Vanek V. Meta-analysis of effectiveness of intermittent pneumatic compression devices with a comparison of thigh-high to knee-high sleeves. Am Surg. 64:1998;1050-1058.
39. Agu O., Hamilton G., Baker D. Graduated compression stockings in the prevention of venous thromboembolism. Br J Surg. 86:1999;992-1004.
40. Comerota A.J., Katz M.L., White J.V. Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg. 164:1992;265-268.
41. Agnelli G., Piovella F., Buoncristiani P., Severi P., Pini M., D'Angelo A., et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 339:1998;80-85.
42. Turpie A.G., Hirsh J., Gent M., Julian D., Johnson J. Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med. 149:1989;679-681.
43. Goldhaber S.Z., Hirsch D.R., MacDougall R.C., Polak J.F., Creager M.A., Cohn L.H. Prevention of venous thrombosis after coronary artery bypass surgery (a randomized trial comparing two mechanical prophylaxis strategies). Am J Cardiol. 76:1995;993-996.
44. Cohen A.T., Khushal A. Extended thromboprophylaxis following lower limb arthroplasty: what do the clinical trials mean? Haemostasis. 30:(Suppl 2):2000;88-94.
45. Valladares J.B., Hankinson J. Incidence of lower extremity deep vein thrombosis in neurosurgical patients. Neurosurgery. 6:1980;138-141.
46. Sawaya R., Zuccarello M., El-Kalliny M. Brain tumors and thromboembolism: clinical, hemostatic, and biochemical correlations. [abstract 23] J Neurosurg. 70:1989;314A.
47. Turpie A.G., Gallus A., Beattie W.S., Hirsh J. Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology. 27:1977;435-438.
48. Skillman J.J., Collins R.E., Coe N.P., Goldstein B.S., Shapiro R.M., Zervas N.T., et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. Surgery. 83:1978;354-358.
49. Carman T.L., Kanner A.A., Barnett G.H., Deitcher S.R. Prevention of thromboembolism after neurosurgery for brain and spinal tumors. South Med J. 96:2003;17-22.
50. Black P.M., Crowell R.M., Abbott W.M. External pneumatic calf compression reduces deep venous thrombosis in patients with ruptured intracranial aneurysms. Neurosurgery. 18:1986;25-28.
51. Dickinson L.D., Miller L.D., Patel C.P., Gupta S.K. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery. 43:1998;1074-1081.
52. Macdonald R.L., Amidei C., Baron J., Weir B., Brown F., Erickson R.K., et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol. 59:2003;362-372.
53. Goldhaber S.Z., Dunn K., Gerhard-Herman M., Park J.K., Black P.M. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest. 122:2002;1933-1937.
54. Cerrato D., Ariano C., Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg. 49:1978;378-381.
55. Frim D.M., Barker F.G. II, Poletti C.E., Hamilton A.J. Postoperative low-dose heparin decreases thromboembolic complications in neurosurgical patients. Neurosurgery. 30:1992;830-832.
56. Dolovich L.R., Ginsberg J.S., Douketis J.D., Holbrook A.M., Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 160:2000;181-188.
57. Levine M., Gent M., Hirsh J., Leclerc J., Anderson D., Weitz J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 334:1996;677-681.
58. Merli G., Spiro T.E., Olsson C.G., Abildgaard U., Davidson B.L., Eldor A., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 134:2001;191-202.
59. Simonneau G., Sors H., Charbonnier B., Page Y., Laaban J.P., Azarian R., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE study group. Tinzaparine ou heparine standard: evaluations dans l'embolie pulmonaire. N Engl J Med. 337:1997;663-669.
60. Raschke R.A., Reilly B.M., Guidry J.R., Fontana J.R., Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med. 119:1993;874-881.
61. Hyers T.M., Agnelli G., Hull R.D., Morris T.A., Samama M., Tapson V., et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 199:(Suppl 1):2001;176S-193S.
62. van Der Heijden J.F., Hutten B.A., Buller H.R., Prins M.H. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev. (1):2002;CD002001.
63. Greinacher A., Volpel H., Janssens U., Hach-Wunderle V., Kemkes-Matthes B., Eichler P., et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 99:1999;73-80.
64. Lewis B.E., Walenga J.M., Wallis D.E. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost. 23:1997;197-202.
65. Schulman S., Rhedin A.S., Lindmarker P., Carlsson A., Larfars G., Nicol P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 332:1995;1661-1665.
66. Pinede L., Ninet J., Duhaut P., Chabaud S., Demolombe-Rague S., Durieu I., et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 103:2001;2453-2460.
67. Deitcher S.R., Carman T.L. Deep venous thrombosis and pulmonary embolism. Curr Treat Options Cardiovasc Med. 4:2002;223-238.
68. Ridker P.M., Goldhaber S.Z., Danielson E., Rosenberg Y., Eby C.S., Deitcher S.R., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 348:2003;1425-1434.
69. Carman T.L., Fernandez B.B. Jr. Issues and controversies in venous thromboembolism. Cleve Clin J Med. 66:1999;113-123.
70. Lazio B.E., Simard J.M. Anticoagulation in neurosurgical patients. Neurosurgery. 45:1999;838-847.
71. Decousus H., Leizorovicz A., Parent F., Page Y., Tardy B., Girard P., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 338:1998;409-415.
72. International Stroke Trial Collaborative Group. The International Stroke Trial (IST). A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 349:1997;1569-1581.
73. Bath P.M., Lindenstrom E., Boysen G., De Deyn P., Friis P., Leys D., et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 358:2001;702-710. [erratum: Lancet 2001;358:1276].
74. Kelly J., Rudd A., Lewis R., Hunt B.J. Venous thromboembolism after acute stroke. Stroke. 32:2001;262-267.
75. Schiff D., DeAngelis L.M. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 73:1994;493-498.
76. Morales A., Adelstein D.J. Should a patient with a brain tumor receive anticoagulation for a thromboembolic event? Cleve Clin J Med. 68:(1):2001;13. 16.
77. Olin J.W., Young J.R., Graor R.A., Ruschhaupt W.F., Beven E.G., Bay J.W. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter? Arch Intern Med. 147:1987;2177-2179.
78. Douketis J.D. Perioperative anticoagulation management in patients who are receiving oral anticoagulation therapy: a practical guide for clinicians. Thromb Res. 108:2003;3-13.